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Abstract 
A reformulation of Mycobacterium cell wall fraction immunotherapeutic can be used to successfully treat 
sarcoids in horses. Sarcoids are reported to be the most common equine skin tumors with tumor type 
and location influencing the choice of treatment. Wide surgical excision is curative for many tumors, but 
may not always be feasible. Previous studies have reported sarcoid regression after injection with 
mycobacterial cell wall immunotherapeutics. A new formulation of the Mycobacterium phlei cell wall 
fraction immunostimulant (Immunocidin® Equine) was utilized to treat cutaneous tumors in horses. 
Equids with skin tumors diagnosed as sarcoids were enrolled in the study. Sarcoids were injected at the 
initial visit with Immunocidin® Equine and subsequently at approximately 2-week intervals. Of 17 cases, 9 
cases were completely resolved at the end of the study period evaluation or at time of final follow up 
(52.9%). Three cases were reported as improved (smaller), but not resolved (17.6%). Three cases were 
discontinued from the study as the respective masses were growing larger or not resolving (17.6%). One 
case (5.8%) with two masses had resolution of one mass, whereas the other tumor had a small regrowth 
5 months after the last treatment. One case (5.8%) was lost to follow up. All cases had mild to moderate 
swelling of the injection site, and some cases had discharge after the second, third, or fourth injections. 
No serious systemic side effects or complications were encountered during the study. 
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Abstract 13 
A reformulation of Mycobacterium cell wall fraction immunotherapeutic can be used to 14 
successfully treat sarcoids in horses.  Sarcoids are reported to be the most common equine skin 15 
tumors with tumor type and location influencing the choice of treatment. Wide surgical excision 16 
is curative for many tumors, but may not always be feasible. Previous studies have reported 17 
sarcoid regression after injection with mycobacterial cell wall immunotherapeutics.  A new 18 
formulation of the Mycobacterium phlei cell wall fraction immunostimulant (Immunocidin® 19 
Equine) was utilized to treat cutaneous tumors in horses.  Equids with skin tumors diagnosed as 20 
sarcoids were enrolled in the study. Sarcoids were injected at the initial visit with Immunocidin® 21 
Equine and subsequently at approximately 2-week intervals.  Of 17 cases, 9 cases were 22 
completely resolved at the end of the study period evaluation or at time of final follow up 23 
(52.9%). Three cases were reported as improved (smaller), but not resolved (17.6%). Three cases 24 
were discontinued from the study as the respective masses were growing larger or not resolving 25 
(17.6%). One case (5.8%) with two masses had resolution of one mass, whereas the other tumor 26 
had a small regrowth 5 months after the last treatment.  One case (5.8%) was lost to follow up.  27 
All cases had mild to moderate swelling of the injection site, and some cases had discharge after 28 
the second, third, or fourth injections.  No serious systemic side effects or complications were 29 
encountered during the study. 30 
 31 
1. Introduction 32 
Equids (horses, mules, donkeys, zebras) can be afflicted with various types of skin tumors.  Up 33 
to 30% of cases presented for equine dermatologic disease are afflicted with cutaneous neoplasia 34 
[1,2].  In a large survey of submissions from 2 laboratories over 10 years, neoplastic disease was 35 
present in 65% of submitted samples [1].  Sarcoids are the most common type of skin tumor [1]. 36 
Many treatments have been used for sarcoids and other skin tumors including local topical and 37 
injectable therapies; response to treatment is varied and may differ depending on tumor type, 38 
tumor stage, prior treatment and location [3,6-14].  Some tumors appear to be cured with 39 
complete surgical removal [4,5,6], but wide surgical removal is not always feasible.  Sarcoids 40 
often occur on the head, and in other locations that may make surgical removal difficult [6].  In 41 
addition, the variable appearance and characteristics of sarcoids can make it hard to determine 42 
prognosis [6].  No treatment for sarcoids appears to be efficacious in all cases.   43 
 44 
Cell wall skeletons purified from bacteria have been used for many years for both human and 45 
veterinary anticancer treatments [15-20].  Attenuated Mycobacterium bovis strain bacille 46 
Calmette-Guérin (BCG), and extracts from other Mycobacterium species, Corynebacterium 47 
species and other bacteria have been used as anticancer agents [18].  These immunotherapies 48 
have been found to be very effective in inducing cytokine synthesis by immune cells and 49 
activation of immune cells, as well as inducing apoptosis of cancer cells [16,18]. Side effects 50 
from bacterial cell wall products can occur and include edema, pain, tissue necrosis and 51 
discharge [14,19-22].  Previous studies report equine sarcoid regression after injection with 52 
mycobacterial cell wall products [14,19-22].  53 
For this study, a newer formulation of a Mycobacterium cell wall fraction with a purportedly 54 
wider safety margin [23,24] was utilized to treat cutaneous tumors in horses.  Regressin®
 
55 
(Bioniche Animal Health, Ontario, Canada) was an early anticancer immunotherapeutic used in 56 
animals.  Immunocidin® Equine (Novavive Inc., Napanee, Ontario, Canada) is a reformulation 57 
of the original Regressin. Both products are based on the same Mycobacterium phlei organism.  58 
Regressin was a veterinary biologic product regulated as a poorly defined and variable sized 59 
mycobacterial cell wall extract (MCWE) and was an extract of the cell wall and other elements 60 
from M. phlei.  Immunocidin is a veterinary biologic product regulated as a defined 61 
mycobacterium cell wall fraction (MCWF), and is purified fragments of M. phlei cell wall.  The 62 
carrier for Regressin was phosphate buffered saline (PBS) in a 2% mineral oil emulsion; 63 
Immunocidin is formulated with M. phlei fractions in squalane droplets (2%) in a PBS carrier.  64 
Squalane is the fully hydrogenated form of squalene, an organic compound that is the precursor 65 
of cholesterols and steroid hormones [25].   66 
 67 
 68 
Our hypothesis was that treatment with Immunocidin would reduce tumor mass after repeated 69 
local injection of the tumor. 70 
 71 
2. Materials and Methods 72 
2.1. Study Design 73 
The study was approved by the Institutional Animal Care and Use Committee (IACUC) at Iowa 74 
State University.  Client-owned equids that presented to the authors’ hospital for evaluation of 75 
cutaneous masses were enrolled in the study.  Cases were prospectively enrolled in this open-76 
label clinical trial by recruitment of cases presenting for skin tumor treatment. Owners were 77 
informed of the study aims, procedures, risks and aftercare and indicated their consent for 78 
inclusion in this study by signing a consent form approved by IACUC.   Inclusion criteria were 79 
horses with single or multiple masses presumptively diagnosed as sarcoids during physical exam, 80 
and which did not exceed 5 cm diameter. In case where multiple tumors were present, the largest 81 
mass was not to exceed 5cm in diameter.  The size restriction was chosen to limit variability for 82 
this trial.  Signalment and tumor location were recorded. A physical examination was used to 83 
assess general health.  Only 1-3 of the largest tumors were injected while small adjunct masses 84 
or ones in close proximity to the largest injected tumor were left untreated.  Initial work-up 85 
included history, physical examination, tumor biopsy, tumor measurement and photography. A 4 86 
or 6 mm punch biopsy instrument was used to obtain a sample of the mass during the initial 87 
examination.  Biopsies were evaluated by a boarded pathologist to establish a histopathologic 88 
diagnosis.   89 
 90 
2.2. Injection 91 
Volume of injection was calculated with the following formula suggested by the product 92 
manufacturer:  Length (cm) x Width (cm) = cm2 x 0.78 (used for ‘rounding’ the corners of the L 93 
x W multiple) = calculated cm2 x 0.5 ml = X ml (total volume to be injected).  Minimum 94 
recommended dose is 0.5 ml/ cm2 tumor surface area.  Injections were performed with a 22-95 
gauge needle (or 20 gauge if a dense fibrous sarcoid) into the mass in a grid pattern.  Needles 96 
were placed approximately 0.8 cm apart and a total of 2/3 the calculated dose was injected into 97 
the tumor using the grid pattern.  One third of the calculated dose was also injected under the 98 
tumor.   99 
 100 
2.3. Monitoring and Additional Treatment 101 
Horses received examination and treatments every 14 days.  If no visible tumor were present at 102 
recheck, then an additional 14 day recheck was recommended and no treatment was performed at 103 
that time.  If the tumor were still visible, an additional treatment was performed at that time.  If 104 
no change in mass size or consistency was seen after 4 injections, or if the tumor were growing 105 
larger during treatment, then treatment was discontinued and other methods such as surgical 106 
removal or chemotherapy were recommended to treat the tumor.  Tumors were photographed 107 
and measured at each visit prior to re-injection.  Any adverse events were recorded, including but 108 
not limited to swelling, discharge, tissue necrosis, pain, scarring.  Owners were notified in 109 
advance of treatment of possible side effects.  Tumors were considered resolved or regressed if 110 
the original mass(es) were gone at last evaluation or at final follow up.  Tumor resolution was 111 
defined as the skin appeared normal or had a scar (but no visible tumor tissue).   112 
 113 
2.4. Statistical analysis 114 
Tumor size was calculated at each time point using the following formula: Length (cm) x Width 115 
(cm) = cm2. Data sets were tested for normality with the Shapiro–Wilk test and found to be not 116 
normally distributed.  Differences in in tumor size between time points were analyzed by the 117 
one-way Friedman repeated measures analysis of variance on ranks with Student -Newman-118 
Keuls post-hoc test for multiple comparisons. Data were presented as median and interquartiles 119 
or ranges. Commercial software (GraphPad Software, San Diego, California) was used for 120 
statistical analyses with significance established at P < 0.05. 121 
 122 
3. Results 123 
3.1. Horses 124 
Twenty-one equids ranging in age from 4 to 23 years (median 11 years), were initially enrolled 125 
in the study. Histopathologic diagnosis was reported as sarcoid for 16 cases; 1 case was 126 
diagnosed as a peripheral nerve sheath tumor, which is a histologic diagnosis often given for 127 
sarcoids (see discussion).  Histologically, 4 of the cutaneous lesions were diagnosed as other 128 
masses, despite appearing to be sarcoids based on examination.  One case was diagnosed as a 129 
“suspect cyst or neoplasm”, and three cases as dermatitis.  Only the cases diagnosed as sarcoid or 130 
peripheral nerve sheath tumor were statistically analyzed for comparison.  Breeds or species 131 
included in the final analysis  included 10 Quarter Horses, 3 Thoroughbreds, one each of 132 
Missouri Fox Trotter, Paint, draft cross, and warmblood.  A summary of results is provided in 133 
Table 1.   134 
 135 
3.2. Case Outcome 136 
Complete data sets were available for analysis for 15 horses on days 0, day 14, 28 and 42. If 137 
tumor was resolved, a value of 0 was given for the size measurement.  Differences in the tumor 138 
size between time points are presented in Figure 1. The median tumor size was significantly 139 
smaller on day 42 and 28 compared to day 14 (P<0.05).  Of 17 cases, 9 (52.9%) cases were 140 
completely resolved at the end of the study period evaluation or at the time of final follow up 141 
(see examples in Figures 2 and 3). Three cases were reported to have improved (were smaller), 142 
but did not resolve (17.6%). Three cases were discontinued from the study as the respective 143 
masses were growing larger or not resolving (17.6%).  One of those cases had no appreciable 144 
change in size during treatment and was slightly larger 1 month after the last treatment, but has 145 
remained static since that time.   Another case had a noticeable increase of size of the tumor and 146 
treatments were discontinued after the third injection; the tumor was surgically removed and the 147 
base of the tumor treated with imiquimod.   The third case was not responding to treatment and 148 
discontinued, but additional treatments or surgical procedures of the mass are unknown.  One 149 
case (5.8%) with two masses had resolution of one mass, whereas the other tumor had a small 150 
regrowth 5 months after the last treatment; the regrowth was treated with CO2 laser ablation and 151 
imiquimod after which both masses have remained resolved. One case (5.8%) was completely 152 
lost to follow up and outcome could not be determined despite repeated attempts to contact 153 
owner and referring veterinarian. 154 
 155 
3.3. Treatments and Side Effects 156 
The number of injections completed ranged from 2-5 injections (median 4).  Volume injected 157 
during treatments varied based on size of tumor according to the manufacturer’s recommended 158 
formula.  Average injection volume was 4.6 milliliters (ml), range 0.5-14 ml).  All cases had 159 
swelling at the site of injection and the immediate surrounding area following injection, typically 160 
starting at about 24-48 hours post injection.  Swelling gradually resolved, but sometimes took 161 
several weeks and up to 3 months to completely return to normal.  Swelling was typically firm in 162 
the area just under and around the injection site.  Pitting edema was evident in many cases 163 
around or ventral to the injection site.  Six cases had discharge of purulent appearing material 164 
from the injection site and/or mild sloughing of superficial tissues (Figure 4).  Discharge 165 
occurred after the 2nd, 3rd or 4th injection (not after the first injection).  All owners were 166 
instructed to administer NSAIDS if needed in the event that significant swelling or soreness 167 
occurred.  Injection was well tolerated in most cases; some horses required sedation or twitch 168 
application for the injections. 169 
 170 
3.4. Follow up 171 
Final follow up was available for 16 cases, and time from last treatment to final follow up 172 
averaged 9 months (ranged 4 - 17 months).  Follow up with the owner and/or referring 173 
veterinarian was completed by phone and/or email communication.  In some cases, follow up 174 
was completed during examination by the authors at a recheck examination or during a visit to 175 
our clinic for another reason. If the owner or referring veterinarian reported the outcome, they 176 
were asked to report presence of any remaining mass after treatment, regrowth of new masses, 177 
and the presence of scar tissue.  When possible, photos were obtained to corroborate owner or 178 
referring veterinarian follow up information given, as seen in Figure 5.  One case did not show 179 
up for appointments for treatments and recheck examinations after the second treatment, but the 180 
owner did later respond to follow up communication and reported that the mass had resolved and 181 
not returned.  One case was completely lost to follow up.  The owner did not show up for their 182 
second appointment and did not return further communications, thus no final outcome could be 183 
obtained for this cases.  Three cases were withdrawn from the study due to treatment failure; 184 
masses were getting larger despite treatment. 185 
 186 
4. Discussion 187 
Our findings indicate that Immunocidin® Equine was effective in 52.9% of the cases enrolled 188 
that had a known outcome, after 2-5 injections.  The treatment was safe, and although the side 189 
effect of swelling occurred in every case, swelling of the injection site was transient and resolved 190 
with no other treatment than NSAID administration.  Regression rates in these cases are similar 191 
to previous reports of sarcoid treatment with BCG [5,14,26-28]. Although not statistically 192 
significant (P=0.08), there was an increase in the median tumor size 14 days after the initial 193 
treatment. This transient increase in tumor size may be explained with inflammation from the 194 
injection. 195 
 196 
Mycobacteria and their cell wall components have been used to treat a variety of tumors in both 197 
human and veterinary patients [6,14,22-29].  Treatments prepared from mycobacterial 198 
components are typically described or defined as non-specific immunotherapies; their ability to 199 
stimulate the immune system has been well studied [18].  Mycobacterial cell complexes induce 200 
cytokine synthesis and apoptosis, and activate immune effector cells [16-18].  T-lymphocytes are 201 
important elements of the anti-tumor response to mycobacterial cell wall-based treatments [17].  202 
Toll-like receptors, which are expressed on dendritic cells and macrophages, recognize many 203 
microbial structures.  Mycobacterial antigens stimulate these cells through specific toll-like 204 
receptors, and rapid activation of the innate immune system occurs [30].  In some studies, 205 
mycobacterial cell complexes have also been shown to inhibit cellular proliferation of cancer cell 206 
lines [16].   Mycobacterial cell complexes have been reported in some human studies to have a 207 
better toxicity profile than BCG [23,24].  No explicit statements of pretreatment for anaphylaxis 208 
were reported in these studies, but some practitioners report pre-treating with nonsteroidal anti-209 
inflammatories before the use of BCG.  The authors did not pre-treat with anti-inflammatory 210 
medications during this study, but did advise owners to administer NSAIDS if needed in the 211 
event that significant swelling or soreness occurred.  Our study supports a low rate of serious 212 
adverse events with the use of MCWE, although we recognize our study population is small.  213 
 214 
Not all masses in this study were diagnosed by histopathology as sarcoids.  Because biopsies 215 
were taken at the time of the first treatment, and histopathology was not completed until later, 216 
some masses were diagnosed as sarcoids based on clinical exam, but subsequent histopathologic 217 
diagnosis for 2 cases were determined to be eosinophilic dermatitis and ‘suspect cyst or 218 
neoplasm’ for one case.  Although these cases were not included in the final analysis, 2 of these 219 
3 cases resolved after treatment, indicating that this product might be a useful treatment for 220 
masses other than sarcoids.  It is possible, however, these masses may have resolved without 221 
treatment.  Diagnosis of masses that appear to be sarcoids may not be confirmed with 222 
histopathology for several reasons; as their diagnosis by histopathology has challenges and 223 
limitations [28].  Other authors have noted that the histologic appearance of sarcoid fibroblasts 224 
are not different from normal fibroblasts, and that diagnoses of fibroma, fibroscarcoma, and 225 
nerve sheath tumors are sometimes made in cases that later were discovered to be sarcoids [28].  226 
The authors did include the one cased diagnosed as peripheral nerve sheath tumor in the final 227 
analysis for this reason.  Additionally, because the treatment in this study was an injection and 228 
the authors sought to preserve tumor mass to monitor response to this treatment, the biopsies 229 
taken were small (4-6 mm) punch biopsy samples instead of larger excisional biopsy tissue 230 
samples.  Such small samples may have provided an inadequate amounts of tissue, especially if 231 
inadvertently taken from an area of the mass with only associated inflammatory changes, or 232 
without changes characteristic of sarcoids. 233 
 234 
It has been reported previously that different types of sarcoids respond differently to therapy, 235 
including immunotherapy such as BCG [22,28].  Our analysis of percent change in tumor size 236 
when compared by location or type of tumor did not reveal any statistically significant 237 
differences.  These results are shown in Figures 6 and 7.  A larger sample size would be 238 
necessary to further discriminate among the different sarcoid types and locations with respect to 239 
treatment response. 240 
 241 
Three cases were improved or smaller, but not completely resolved.  It is possible with further 242 
injections, that resolution may have been achieved.  While these three masses were reported to 243 
be smaller than at initial examination and quiescent at the time of follow up, owners either chose 244 
to not pursue further treatment at all, or chose to pursue a different treatment at a later date.  One 245 
difficulty in conducting clinical trials is continued client participation.  In this study, participants 246 
were asked to bring their horses for examinations and treatments every 2 weeks.  Some clients 247 
found the effort to trailer horses to our clinic so frequently burdensome, especially if they 248 
traveled longer distances.  Conducting the examinations and treatments on farm may have 249 
increased compliance, but the authors in this study were not primary ambulatory practitioners, 250 
and many cases that were enrolled were outside of our ambulatory radius.  Evaluation of the final 251 
outcome can also be difficult during clinical trials if the patient is not re-presented to the clinic.  252 
If owners or referring veterinarians are contacted and no response obtained, final outcome is not 253 
known and these cases cannot be included in final analysis; thus, there is loss of data.  In this 254 
study, most owners were relatively easy to contact, responded, and were willing to answer follow 255 
up questions. 256 
 257 
5. Conclusions 258 
This reformulation of mycobacterial cell wall fraction for use in horses, Immunocidin® Equine, 259 
appears to be a safe and effective treatment for some sarcoids.  Though they were transient and 260 
resolved with either no treatment or with the use of NSAIDs, owners and veterinarians should be 261 
aware of the likelihood of post injection complications including swelling and possible discharge 262 
from the site of injection.  The mycobacterial cell wall product studied appears to be viable and 263 
reasonably effective option for the treatment of sarcoids in equine patients, which remains an 264 
important cause of pathology in horses, and a sometimes difficult condition to treat. 265 
 266 
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Table 1. 354 
 355 
  
Histopathologic 
diagnosis 
     
 
  
Age 
(years) Breed Location Mass Type Day 0 Day 14 Day 28 Day 42 
 
 
 
 
 
 
% 
Change 
in tumor 
size Day 
0 to Day 
42 
Outcome at final 
follow up 
Duration - last 
treatment to final 
follow up 
18 Paint Peripheral nerve 
sheath tumor 
R neck occult 4.1 cm x 
2.8 cm 
3.6 cm x 
1.3 cm 
-  0 -100.00 Resolved 16 mos 
12 QH Sarcoid R periocular nodular 1.7 cm x 
2.0 cm 
2.7 cm x 
3.2 cm 
appeared 
resolved 
0 -100.00 Resolved 14 mos 
5 Draft 
cross 
Sarcoid L TMJ area occult and 
nodular 
2.5 cm x 
2.5 cm 
3.4 cm x 
1.9 cm 
2.5 cm x 
1.6 cm 
0 -100.00 One mass resolved.  
One resolved then 
regrowth 5 mos after 
last tx.  
12 mos 
12 QH Sarcoid R sheath 
and inguinal 
area 
fibroblastic 4.0 cm x 
2.5 cm 
- - -  Tx failure;  masses 
getting larger 
Withdrawn from 
study before 2nd visit 
16 TB Sarcoid LH heel 
bulb 
fibroblastic 4.3 cm x 
5.3 cm 
3.8 cm x 
7.2 cm 
3.8 cm x 
5.5 cm 
3.8 cm x 
5.5 cm 
-8.29 Improved.  Smaller 
but not gone. 
7 mos 
13 QH Sarcoid Chest, 
periocular, 
elbow, 
shoulder 
nodular and 
verrucose 
2.5 cm x 
3.0 cm 
4.3 cm x 
4.3 cm 
2.7 cm x 
3.1 cm 
2.0 cm x 
3.1 cm 
17.33 Resolved  17 mos 
11 QH Sarcoid L prepuce mixed 3.1 cm x 
3.2 cm 
3.1 cm x 
4.8 cm 
3.5 cm x 
3.2 cm 
4.0 cm x 
2.0 cm 
-19.35 Resolved 9 mos 
5 M Fox 
Trotter 
Sarcoid R cheek fibroblastic 3.6 cm x 
4.8 cm 
3.0 cm x 
4.2 cm 
2.8 cm x 
3.6 cm 
3.0 cm x 
3.5 cm 
-39.24 Improved. Smaller 
but not gone.  
8 mos 
7 QH Sarcoid L chest verrucose 4.5 cm x 
3.6 cm 
4.0 cm x 
3.5 cm 
4.0 cm x 
3.5 cm 
4.0 cm x 
4.1 cm 
1.23 Improved. Smaller 
but not gone 
5 mos 
11 QH Sarcoid LH pastern fibroblastic 1.3 cm x 
1.5 cm 
1.5 cm x 
1.5 cm 
1.5 cm x 
2.0 cm 
2.1 cm x 
2.5 cm 
5.25 Tx failure; mass 
getting larger. 
Withdrawn from 
study at 4th visit 
5 QH Sarcoid L neck nodular  0.5 cm x 
0.6 cm 
0.9 cm x 
1.0 cm 
0.76 cm x 
1.14 cm 
 0 -100.00 Resolved 12 mos 
4 QH Sarcoid R neck,  L 
ear 
nodular and 
occult 
4.5 cm x 
5.2 cm 
5.3 cm x 
7.0 cm 
4.0 cm x 
7.0 cm 
4.0 cm x 
7.5 cm 
28.21 Resolved 4 mos 
13 WB Sarcoid R ear fibroblastic 3.2 cm x 
3.6 cm 
- - -  Lost to follow up Lost to follow up 
7 TB Sarcoid R periocular nodular and 
occult 
4.0 cm x 
5.0 cm 
3.4 cm x 
4.0 cm 
3.4 cm x 
4.0 cm 
3.8 cm x 
3.8 cm 
-27.8 Resolved 5 mos 
7 TB Sarcoid L shoulder occult 2.5 cm x 
2.3 cm 
2.0 cm x 
1.5 cm 
sloughed 
off 
0 -100.00 Resolved 4 mos 
12 QH Sarcoid R chest fibroblastic 3.0 cm x 
2.2 cm 
2.8 cm x 
2.5 cm 
2.3 cm x 
2.2 cm 
2.6 cm x 
2.5 cm 
-1.52 Tx failure.  Mass 
slightly larger at 7 
mos post tx. 
Withdrawn from 
study at 4th visit 
11 QH Sarcoid RH dorsal 
cannon 
mixed 2.0 cm x 
2.3 cm 
1.9 cm x 
1.9 cm 
1.5 cm x 
2.4 cm 
1.1 cm x 
2.2 cm 
-47.39 Resolved 6 mos 
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 359 
 360 
Figure Legends 361 
 362 
Figure 1  Differences in tumor sizes (centimeters squared) (n=15) between time points (day).  363 
Asterisk denotes statistically significant difference (P<0.05). Median and interquartiles. 364 
 365 
Figure 2  Sarcoid on the prepuce in an 11-year-old Quarterhorse gelding before (A), during (B), 366 
and after (C) treatment. 367 
 368 
Figure 3  Periorbital sarcoid in a 7-year-old Thoroughbred gelding before (A), during (B), and 369 
after (C) treatment. 370 
 371 
Figure 4 Sarcoid on the neck in a 4-year-old Quarterhorse gelding exhibiting purulent appearing 372 
material from the injection site and sloughing of superficial tissues. 373 
 374 
Figure 5  The same horse from Figure 4 after resolution and healing of the treatment site, 5 375 
months after the last treatment.  A scar is present at the site of treatment. 376 
 377 
Figure 6 Median change in tumor size (percent change) from day 0 to day 42 by location. 378 
 379 
Figure 7 Median change in tumor size (percent change) from day 0 to day 42 by tumor type. 380 







 Highlights 
 
Mycobacterial cell wall fractions can be used to successfully treat some sarcoids in horses. 
 
Mycobacterial immunotherapies induce cytokine synthesis, apoptosis, activate immune cells. 
 
Minimal side effects of swelling and discharge are common with mycobacterial cell wall 
immunotherapies. 
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